Blog
Bem-vindo ao nosso blog - seu novo canal de informações para notícias, lançamento de produtos, artigos científicos, estudos de caso e muito mais.
View all blogs:
Lipid technology for delivery of gene editing therapies
Gene-editing is one of the most eagerly anticipated biopharma developments in recent history. However, one of the biggest hurdles to the development of successful gene-editing therapeutics is...
Sustentabilidade em excipientes – Uma perspectiva do usuário e do fornecedor
Para alcançar suas metas de sustentabilidade, os usuários de excipientes necessitam de acesso a excipientes com menores emissões de gases de efeito estufa incorporadas, produção reduzida de resíduos e...
Things to consider when choosing a cationic lipid for your formulation
Lipid-based therapeutic delivery systems have been evolving for many years. From delivering naked mRNA, to using liposomes, and now lipid nanoparticles,
Proprietary purification process extends formulation shelf life
Formulating generic drugs of equivalent stability, safety, bioequivalence, and dosage form as originator drugs can be a great challenge. James Humphrey, Research and Technology Specialist explores how...
Our Healthcare division becomes Croda Pharma
Croda International Plc, the company that uses smart science to create high performance ingredients and solutions that improve lives, has today announced that its Health Care division will now become...
Croda Pharma wins prestigious “Best Supplier for COVID-19 Vaccine Development 2022” Award
Croda, the company that uses smart science to improve lives, announces that it has been awarded winner a prestigious award for its work in supporting vaccine development. The company has been awarded...
Exclusive license for Croda to commercialise SSI’s CAF® vaccine adjuvants
Croda International Plc, which uses smart science to improve lives, announces today that it has entered a strategic collaboration with Statens Serum Institut (“SSI”), the leading Danish Governmental...
Croda expands its high purity pharmaceutical excipients manufacturing capability
This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve...
Strengthening Life Sciences with the acquisition of Avanti Polar Lipids
13 August 2020: A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.